相似文献
1
Priming by DNA immunization augments protective efficacy of Mycobacterium bovis Bacille Calmette-Guerin against tuberculosis.
Infect Immun. 2001 Jun;69(6):4174-6. doi: 10.1128/IAI.69.6.4174-4176.2001.
2
Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis.
J Infect Dis. 2008 May 1;197(9):1263-74. doi: 10.1086/586902.
3
Priming but not boosting with plasmid DNA encoding mycolyl-transferase Ag85A from Mycobacterium tuberculosis increases the survival time of Mycobacterium bovis BCG vaccinated mice against low dose intravenous challenge with M. tuberculosis H37Rv.
Vaccine. 2006 Apr 12;24(16):3353-64. doi: 10.1016/j.vaccine.2005.12.066. Epub 2006 Feb 6.
4
A novel DNA vaccine for protective immunity against virulent Mycobacterium bovis in mice.
Immunol Lett. 2008 May 15;117(2):136-45. doi: 10.1016/j.imlet.2008.01.008. Epub 2008 Feb 12.
5
Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells.
Vaccine. 2009 Jan 1;27(1):28-37. doi: 10.1016/j.vaccine.2008.10.034. Epub 2008 Oct 31.
6
Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice.
FEMS Immunol Med Microbiol. 2007 Dec;51(3):480-7. doi: 10.1111/j.1574-695X.2007.00322.x. Epub 2007 Oct 4.
7
Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection.
Vaccine. 2005 Feb 25;23(14):1680-5. doi: 10.1016/j.vaccine.2004.10.007.
8
Investigation of immunogenic effect of the BCG priming and Ag85A- GM-CSF boosting in Balb/c mice model.
Immunobiology. 2010;215(2):133-42. doi: 10.1016/j.imbio.2009.04.002. Epub 2009 May 17.
9
Protection against Mycobacterium tuberculosis challenge in mice by DNA vaccine Ag85A-ESAT-6-IL-21 priming and BCG boosting.
Int J Immunogenet. 2012 Apr;39(2):183-90. doi: 10.1111/j.1744-313X.2011.01066.x. Epub 2011 Dec 8.
10
Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice.
Scand J Immunol. 2011 Jun;73(6):568-76. doi: 10.1111/j.1365-3083.2011.02531.x.
引用本文的文献
1
Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing.
ACS Nano. 2024 Jul 23;18(31):20083-100. doi: 10.1021/acsnano.4c00949.
2
Heterologous Prime-Boost with Immunologically Orthogonal Protein Nanoparticles for Peptide Immunofocusing.
bioRxiv. 2024 Feb 26:2024.02.24.581861. doi: 10.1101/2024.02.24.581861.
3
Fusion of Dendritic Cells Activating Rv2299c Protein Enhances the Protective Immunity of Ag85B-ESAT6 Vaccine Candidate against Tuberculosis.
Pathogens. 2020 Oct 22;9(11):865. doi: 10.3390/pathogens9110865.
4
A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis.
Iran J Basic Med Sci. 2020 Jun;23(6):826-832. doi: 10.22038/ijbms.2020.41806.9881.
5
A study on the immune response induced by a DNA vaccine encoding Mtb32C-HBHA antigen of .
Iran J Basic Med Sci. 2017 Oct;20(10):1119-1124. doi: 10.22038/IJBMS.2017.9445.
6
Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.
Hum Vaccin Immunother. 2017 Apr 3;13(4):816-822. doi: 10.1080/21645515.2016.1261229. Epub 2016 Dec 14.
7
Increasing the Vaccine Potential of Live M. bovis BCG by Coadministration with Plasmid DNA Encoding a Tuberculosis Prototype Antigen.
Vaccines (Basel). 2014 Mar 5;2(1):181-95. doi: 10.3390/vaccines2010181.
8
Increased B and T Cell Responses in M. bovis Bacille Calmette-Guérin Vaccinated Pigs Co-Immunized with Plasmid DNA Encoding a Prototype Tuberculosis Antigen.
PLoS One. 2015 Jul 14;10(7):e0132288. doi: 10.1371/journal.pone.0132288. eCollection 2015.
9
Analysis of the vaccine potential of plasmid DNA encoding nine mycolactone polyketide synthase domains in Mycobacterium ulcerans infected mice.
PLoS Negl Trop Dis. 2014 Jan 2;8(1):e2604. doi: 10.1371/journal.pntd.0002604. eCollection 2014.
10
Immune response to dna vaccine expressing transferrin binding protein a gene of Pasteurella multocida.
Braz J Microbiol. 2011 Apr;42(2):750-60. doi: 10.1590/S1517-838220110002000043. Epub 2011 Jun 1.
本文引用的文献
1
CD4+ and CD8+ T cells mediate adoptive immunity to aerosol infection of Mycobacterium bovis bacillus Calmette-Guérin.
J Infect Dis. 2000 May;181(5):1846-9. doi: 10.1086/315466. Epub 2000 May 9.
2
CpG oligodeoxynucleotides and interleukin-12 improve the efficacy of Mycobacterium bovis BCG vaccination in mice challenged with M. tuberculosis.
Infect Immun. 2000 May;68(5):2948-53. doi: 10.1128/IAI.68.5.2948-2953.2000.
3
Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice.
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4204-8. doi: 10.1073/pnas.97.8.4204.
4
Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity.
Immunol Rev. 1999 Oct;171:27-44. doi: 10.1111/j.1600-065x.1999.tb01341.x.
5
Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.
Immunol Rev. 1999 Aug;170:29-38. doi: 10.1111/j.1600-065x.1999.tb01326.x.
6
Characterization of human Mycobacterium bovis bacille Calmette-Guérin-reactive CD8+ T cells.
Infect Immun. 1999 Oct;67(10):5223-30. doi: 10.1128/IAI.67.10.5223-5230.1999.
7
Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.
Nat Med. 1999 May;5(5):526-34. doi: 10.1038/8406.
8
Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis.
J Immunol. 1999 May 1;162(9):5407-16.
9
Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis.
Infect Immun. 1999 Apr;67(4):1702-7. doi: 10.1128/IAI.67.4.1702-1707.1999.
10
Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.
J Virol. 1998 Dec;72(12):10180-8. doi: 10.1128/JVI.72.12.10180-10188.1998.
Zotero 插件